Abstract Classic Hodgkin lymphoma (HL) is rare disease, with an incidence of approximately 85,000 patients globally per year and a predilection for adolescents and young adults (ages 15–39). Since the introduction of combination chemotherapy in the 1960's and radiation dating back to the early 1900's, therapeutic options and by extension, clinical outcomes have improved dramatically with 5‐year overall survival (OS) approaching 90% today. [1](#ref‐0001) Advances in understanding HL biology have additionally facilitated development of targeted agents and immunotherapy which have further improved short and long‐term outcomes. Despite continued improvements in up‐front and salvage therapy, long‐term survivors of HL experience several treatment‐associated late toxicities, thus, along with efforts to improve therapeutic efficacy, efforts to reduce late effects remain a high‐priority in the field.